Bulk Pharmaceutical API Sources for MACRILEN

Bulk Pharmaceutical API Sources for MACRILEN

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemLabIndex		CLI1850
MedChemexpress MCE		HY-14820A
Starshine Chemical		2023-05-5H00882
AbaChemScene		CS-0027172

MACRILEN (Tafamidis) Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

What is MACRILEN and its API?

MACRILEN, marketed as Vyndaqel® and Vyndamax® for U.S. patients, is a medication containing the active pharmaceutical ingredient tafamidis. Tafamidis is a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin amyloid polyneuropathy (ATTR-PN) [1]. The drug functions by stabilizing the transthyretin protein, preventing its dissociation into amyloidogenic monomers that deposit in tissues [2].

The bulk API for MACRILEN is tafamidis meglumine or tafamidis free acid. Tafamidis meglumine is the salt form typically used in the formulation of Vyndaqel®, while tafamidis free acid is used in Vyndamax® [3]. The chemical name for tafamidis is 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid. Its molecular formula is C14H7Cl2NO3, and its molecular weight is 324.12 g/mol [4].

Who Manufactures MACRILEN and its API?

Pfizer Inc. is the originator and primary marketer of MACRILEN in key global markets. Pfizer developed tafamidis and holds the primary regulatory approvals. While Pfizer manufactures the final drug product, the synthesis of the bulk API, tafamidis, is often outsourced to contract manufacturing organizations (CMOs) or specialized API manufacturers. Identifying these specific upstream API suppliers can be challenging due to proprietary manufacturing agreements and supply chain confidentiality. However, market analysis and patent filings provide insights into the potential sources and manufacturing capabilities for tafamidis.

What are the Key APIs for MACRILEN?

The primary bulk APIs for MACRILEN are:

• Tafamidis Meglumine: This is the salt form of tafamidis, commonly used in the oral capsule formulations of Vyndaqel®. It is characterized by the meglumine counterion, which enhances solubility and bioavailability.
• Tafamidis Free Acid: This is the un-salt form of tafamidis, utilized in the oral capsule formulations of Vyndamax®. It offers an alternative formulation option, potentially differing in absorption characteristics or stability.

What is the Regulatory Status of Tafamidis API?

The regulatory status of tafamidis API is tied to its approval in the final drug product. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others have approved tafamidis-containing medications. Manufacturers of the bulk API must adhere to Good Manufacturing Practices (GMP) and demonstrate the quality, purity, and consistency of their product through rigorous testing and documentation.

Key regulatory considerations for API manufacturers include:

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, controls, and facilities used for the API. Pharmaceutical companies reference these DMFs in their drug product applications [5].
• GMP Compliance: All API manufacturing must occur in facilities compliant with current Good Manufacturing Practices (cGMP). Regular inspections by regulatory authorities ensure adherence to these standards [6].
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are critical for global API manufacturing standards [7].
• Impurity Profiling: Comprehensive characterization and control of impurities are essential. This includes process-related impurities, degradation products, and residual solvents [8].

Who are the Potential API Manufacturers and Suppliers?

While Pfizer maintains significant control over its supply chain, the global API manufacturing landscape includes numerous specialized companies capable of producing complex small molecules like tafamidis. Identifying specific, publicly disclosed suppliers for tafamidis API is difficult due to confidentiality agreements. However, based on general capabilities in small molecule synthesis and API manufacturing, the following types of companies are likely involved or possess the potential to be involved:

Tier 1: Large Contract Development and Manufacturing Organizations (CDMOs)

These companies have extensive experience in complex organic synthesis, process development, scale-up, and GMP manufacturing for high-value APIs. They often have multi-purpose facilities capable of handling a wide range of chemistries.

• Lonza: A global leader in custom manufacturing, Lonza has extensive expertise in small molecule synthesis and can support API production from clinical to commercial scale.
• Catalent: Offers integrated services including API development and manufacturing, with a focus on complex molecules and sterile APIs.
• Thermo Fisher Scientific (Patheon): Provides comprehensive CDMO services, including API manufacturing for small molecules with expertise in process optimization and GMP compliance.
• Samsung Biologics: While known for biologics, Samsung Biologics has expanded its small molecule API manufacturing capabilities and serves major pharmaceutical clients.
• WuXi AppTec: A leading global CDMO with significant expertise in chemical synthesis, process development, and GMP API manufacturing for a broad range of therapeutic areas.

Tier 2: Specialized Small Molecule API Manufacturers

These companies focus primarily on the production of small molecule APIs, often with specialized technologies or expertise in certain chemical classes.

• ASCA, Inc. (formerly Albany Molecular Research Inc.): Has a long history in custom synthesis and API manufacturing for pharmaceutical clients.
• HPC (Hovione Pharma): A global CDMO with a strong reputation in spray drying and particle engineering, as well as complex API synthesis.
• Aceto: A supplier and manufacturer of specialty materials and APIs, with capabilities in custom synthesis.
• Carbogen Amcis AG: Specializes in the development and GMP manufacturing of complex APIs and potent compounds.
• Almac Group: Offers end-to-end services, including API manufacturing for small molecules, with a focus on quality and regulatory compliance.

Tier 3: Regional and Emerging API Manufacturers

Companies in India and China are significant players in the global API market, known for their cost-effectiveness and growing technical capabilities. While specific involvement with tafamidis is not public, their capacity is substantial.

• Indian API Manufacturers: Companies like Dr. Reddy's Laboratories, Aurobindo Pharma, Sun Pharmaceutical Industries, and Cipla have extensive API manufacturing facilities and are major global suppliers.
• Chinese API Manufacturers: Numerous Chinese companies, including Zhejiang NHU Co., Ltd., and Jiangsu Yew Biotech Co., Ltd., are active in the API market, though often focused on more commoditized products or specific intermediates.

What are the Synthesis Routes for Tafamidis?

The synthesis of tafamidis involves multi-step organic chemistry. While the exact proprietary routes used by Pfizer or its contracted manufacturers are confidential, general synthetic strategies can be inferred from patent literature. A common approach involves the formation of the benzoxazole core followed by introduction of the carboxylic acid moiety or its precursor.

A simplified hypothetical synthetic pathway might involve:

1. Formation of an Anilide Intermediate: Reaction of a substituted aniline (e.g., 4-amino-3,5-dichlorobenzoic acid derivative) with a benzoyl chloride derivative.
2. Cyclization to Benzoxazole: Acid-catalyzed or thermal cyclization of an appropriately substituted 2-aminophenol derivative with a carboxylic acid or its equivalent. For tafamidis, this involves a precursor that ultimately leads to the 2-(3,5-dichlorophenyl)benzoxazole structure with a carboxylic acid group at the 6-position.
3. Introduction of the Carboxylic Acid Group: If not present in the initial building blocks, this might involve oxidation of a methyl group or hydrolysis of a nitrile or ester precursor.

Example Patent Literature Insights:

Patents filed by Pfizer and others often describe various synthetic approaches. For instance, some routes might begin with 2-amino-4-carboxy-phenol derivatives.

• Key Intermediates: Potential key intermediates could include substituted 2-aminophenols and 3,5-dichlorobenzoyl halides or related carboxylic acid derivatives.
• Reaction Conditions: Typical reactions would involve condensation, cyclization, esterification/hydrolysis, and potentially halogenation or other functional group manipulations.
• Process Optimization: For large-scale commercial manufacturing, optimization focuses on yield, purity, cost of goods, safety, and environmental impact. This includes selecting efficient catalysts, solvents, and reaction conditions, and developing robust purification methods.

What are the Key Challenges in API Sourcing for MACRILEN?

Sourcing bulk API for a complex, patented drug like MACRILEN presents several challenges:

• Patent Exclusivity: Pfizer holds patents covering tafamidis, its synthesis, and its use. This significantly restricts the ability of generic manufacturers or alternative suppliers to produce and market the API until patent expiry [9]. Generic companies typically focus on developing alternative synthesis routes to circumvent existing process patents once the primary compound patent has expired.
• Proprietary Manufacturing Processes: The specific, optimized, and validated manufacturing processes are highly proprietary. Any new manufacturer would need to develop their own process or obtain a license, which is unlikely during patent exclusivity.
• High Purity Requirements: Tafamidis is a pharmaceutical API requiring extremely high purity (typically >99%). Achieving and consistently maintaining this purity level demands sophisticated synthesis and purification techniques, as well as stringent quality control.
• Regulatory Hurdles: API manufacturers must meet stringent GMP requirements and pass rigorous inspections by global regulatory bodies. This includes detailed documentation, process validation, and impurity profiling, which can be time-consuming and costly to establish for a new API.
• Supply Chain Security and Reliability: Pharmaceutical companies demand highly reliable and secure supply chains. This involves rigorous vendor qualification, auditing, and often dual-sourcing strategies, which can be difficult to establish for a niche, patented API.
• Cost of Goods: The complex synthesis involved in producing tafamidis contributes to its cost. Optimizing the process to reduce the cost of goods while maintaining quality is a significant challenge.
• Intellectual Property (IP) Landscape: Beyond the primary compound patents, there can be patents covering specific polymorphic forms, crystalline structures, synthesis intermediates, and manufacturing processes. Navigating this IP landscape is critical.

What is the Outlook for Tafamidis API Sourcing?

The outlook for tafamidis API sourcing is heavily dependent on patent expiry and the development of generic alternatives.

• Current Status: As of the current knowledge cutoff, tafamidis is still under patent protection, meaning Pfizer controls the primary market and its associated API supply. Generic entry is not expected until patent expiry.
• Future Generic Entry: Once primary patents expire, generic manufacturers will likely seek to produce tafamidis API. This will open opportunities for CDMOs and specialized API manufacturers to engage with generic drug companies.
• Process Innovation: Generic companies will likely invest in developing non-infringing synthetic routes to tafamidis. This may lead to new process patents and opportunities for API manufacturers with innovative synthesis capabilities.
• Increased Competition: Post-patent expiry, increased competition among API manufacturers is anticipated, potentially driving down API costs.
• Demand Growth: The market for tafamidis is growing due to increased diagnosis and awareness of ATTR-CM and ATTR-PN, suggesting sustained demand for the API.
• Emerging Markets: As regulatory approvals expand and pricing strategies evolve, demand in emerging markets could increase, creating new sourcing opportunities.

Key Takeaways

• MACRILEN's API is tafamidis, existing as tafamidis meglumine or tafamidis free acid.
• Pfizer Inc. is the originator and primary marketer; API manufacturing is likely outsourced to specialized CDMOs and API manufacturers.
• Key API manufacturers operate under strict GMP regulations and must navigate a complex IP landscape.
• Challenges in sourcing include patent exclusivity, proprietary processes, high purity requirements, and regulatory hurdles.
• The future of tafamidis API sourcing will be significantly shaped by patent expiries, leading to generic competition and opportunities for new manufacturers.

FAQs

When do the patents for tafamidis expire?

Patent expiry dates vary by jurisdiction. In the United States, key compound patents for tafamidis have been reported to expire in 2028, with potential for extensions. However, process patents and formulation patents can extend market exclusivity [9].

Can any company manufacture tafamidis API now?

Currently, direct manufacturing and sale of tafamidis API for commercial use by entities other than Pfizer or its authorized licensees are restricted by existing patents covering the compound, its synthesis, and its uses. Generic manufacturing is contingent upon patent expiry.

What are the typical purity standards for pharmaceutical APIs like tafamidis?

Pharmaceutical APIs, including tafamidis, are typically required to have purity levels of 99% or higher. Strict limits are also placed on specific impurities, including residual solvents, heavy metals, and related substances, as defined by pharmacopeial monographs (e.g., USP, EP) and regulatory filings.

How does the meglumine salt form impact API sourcing compared to the free acid?

The choice between tafamidis meglumine and tafamidis free acid can influence the synthesis and purification steps. Salt formation involves an additional reaction step and requires specific counterion sourcing. Purification strategies may also differ to ensure the correct salt stoichiometry and purity. Manufacturers must be equipped to handle either the free acid synthesis and subsequent salt formation or the direct synthesis of the salt.

What is the role of process chemistry in tafamidis API manufacturing?

Process chemistry is critical for developing scalable, cost-effective, and robust manufacturing routes for tafamidis. This involves optimizing reaction conditions, minimizing by-products, developing efficient purification techniques, and ensuring reproducibility and safety at a commercial scale, all while operating within the confines of intellectual property rights.

Citations

[1] Pfizer Inc. (n.d.). Vyndaqel® and Vyndamax®. Retrieved from https://www.vyndaqel.com/

[2] FDA. (2020, April 10). FDA approves new drug for transthyretin amyloid cardiomyopathy. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-drug-transthyretin-amyloid-cardiomyopathy

[3] European Medicines Agency. (2020). Vyndaqel 61 mg soft capsules - Summary of Product Characteristics. Retrieved from EMA website (specific document access may vary).

[4] PubChem. (n.d.). Tafamidis. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Tafamidis

[5] U.S. Food and Drug Administration. (2020). Drug Master Files: An Overview. Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files-overview

[6] U.S. Food and Drug Administration. (2019). Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-finished-pharmaceuticals

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.

[8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances.

[9] GlobalData. (2023, July 25). Tafamidis Market Analysis & Forecast. Retrieved from industry analysis reports (specific report access may be subscription-based).